COVID-19 Transformation to Help Global qPCR and dPCR Instrumentation Market Reach USD 9.2 Billion by 2026
By LabMedica International staff writers Posted on 04 Jun 2021 |

Illustration
The global market for quantitative PCR (qPCR) and digital PCR (dPCR) instrumentation estimated at USD 5.2 billion in 2020 is projected to grow at a CAGR of 9.8% to reach USD 9.2 billion by 2026, driven by opportunities and challenges in a significantly transformed post COVID-19 marketplace.
These are the latest findings of Global Industry Analysts Inc., (San Jose, CA, USA), a market research company.
Real-Time Polymerase Chain Reaction (PCR) also referred to as qPCR analysis, is a modification of the traditional PCR technique. In traditional PCR, the amplified DNA product or amplicon is detected in an end-point analysis by visualization of the DNA product on an agarose gel subsequent to completion of the reaction, which comprises a specified number of amplification cycles. In real-time PCR, however, the accumulation of amplification product is evaluated simultaneously with the progress of the reaction. Product quantification is carried out in real time, after every cycle.
dPCR is an improvement of traditional PCR methods and is utilized to directly quantify as well as clonally amplify nucleic acids such as DNA, RNA, cDNA or methylated DNA. However, digital PCR is at an early stage. The main difference between conventional PCR and dPCR lies in the method used to measure amounts of nucleic acids. Sensitivity of dPCR is high in comparison to qPCR, hence, the technology is particularly used in applications wherein there is a low amount of target sequence. For instance, mutation genes that are found on a very low scale in rare diseases, and HIV DNA that are present in 1,000-10,000 in number within the cell of a patient can be easily detected through the technology.
Amid the COVID-19 crisis, the qPCR segment is projected to grow at a CAGR of 9.3% to USD 8.4 billion, while the dPCR segment is expected to record a CAGR of 13% over the next 7-year period. The dPCR segment currently accounts for a 12.5% share of the global qPCR and dPCR instrumentation market.
Geographically, the US qPCR and dPCR instrumentation market which currently holds a share of 30.8% in the global market was estimated to reach USD 1.9 billion in 2021. The Chinese qPCR and dPCR instrumentation market is projected to grow at a CAGR of 12.2% through the analysis period to reach USD 0.742 billion in 2026. Among the other noteworthy geographies the qPCR and dPCR instrumentation market in Japan and Canada are projected to grow at a CAGR of 8.1% and 8.6%, respectively over the analysis period. Within Europe, Germany is forecasted to grow at a CAGR of approximately 9.1% while Rest of European market is expected to reach USD 0.81 billion by 2026.
While Europe is another large market for qPCR and dPCR instrumentation, the global market growth is expected to be spearheaded by Asia-Pacific. In terms of concentration, a large number of leading companies are located in the US and Europe. However, increasing competition in the markets over the last few years has been driving various players to shift their attention to other promising regions, including Latin America and Asia-Pacific. In Asia-Pacific, the growth of the qPCR and dPCR instrumentation market is being led by the increased use of qPCR in blood donor testing & screening and diagnosis of infectious diseases and tropical diseases such as malaria.
Increasing geriatric population and the resulting incidents of chronic medical conditions such as cancer, coupled with broader application of PCR to study mutations and gene anomalies related to these diseases, are driving the adoption of qPCR and dPCR instrumentation in the Asia-Pacific region. Additionally, the falling cost of nucleic acid detection, quantification, and amplification techniques will also encourage the adoption of qPCR and dPCR instrumentation in research and diagnosis, particularly in the region’s developing, resource poor countries. PCR solution suppliers in Asia-Pacific have been increasingly focusing on establishing or expanding their production and sales network in the region. In recent years, various vendors have shifted their manufacturing units to the region in order to enjoy cost benefits and access the domestic markets, which in turn, is increasing awareness about the technology in the region, thereby contributing to its market growth.
Related Links:
Global Industry Analysts Inc.
These are the latest findings of Global Industry Analysts Inc., (San Jose, CA, USA), a market research company.
Real-Time Polymerase Chain Reaction (PCR) also referred to as qPCR analysis, is a modification of the traditional PCR technique. In traditional PCR, the amplified DNA product or amplicon is detected in an end-point analysis by visualization of the DNA product on an agarose gel subsequent to completion of the reaction, which comprises a specified number of amplification cycles. In real-time PCR, however, the accumulation of amplification product is evaluated simultaneously with the progress of the reaction. Product quantification is carried out in real time, after every cycle.
dPCR is an improvement of traditional PCR methods and is utilized to directly quantify as well as clonally amplify nucleic acids such as DNA, RNA, cDNA or methylated DNA. However, digital PCR is at an early stage. The main difference between conventional PCR and dPCR lies in the method used to measure amounts of nucleic acids. Sensitivity of dPCR is high in comparison to qPCR, hence, the technology is particularly used in applications wherein there is a low amount of target sequence. For instance, mutation genes that are found on a very low scale in rare diseases, and HIV DNA that are present in 1,000-10,000 in number within the cell of a patient can be easily detected through the technology.
Amid the COVID-19 crisis, the qPCR segment is projected to grow at a CAGR of 9.3% to USD 8.4 billion, while the dPCR segment is expected to record a CAGR of 13% over the next 7-year period. The dPCR segment currently accounts for a 12.5% share of the global qPCR and dPCR instrumentation market.
Geographically, the US qPCR and dPCR instrumentation market which currently holds a share of 30.8% in the global market was estimated to reach USD 1.9 billion in 2021. The Chinese qPCR and dPCR instrumentation market is projected to grow at a CAGR of 12.2% through the analysis period to reach USD 0.742 billion in 2026. Among the other noteworthy geographies the qPCR and dPCR instrumentation market in Japan and Canada are projected to grow at a CAGR of 8.1% and 8.6%, respectively over the analysis period. Within Europe, Germany is forecasted to grow at a CAGR of approximately 9.1% while Rest of European market is expected to reach USD 0.81 billion by 2026.
While Europe is another large market for qPCR and dPCR instrumentation, the global market growth is expected to be spearheaded by Asia-Pacific. In terms of concentration, a large number of leading companies are located in the US and Europe. However, increasing competition in the markets over the last few years has been driving various players to shift their attention to other promising regions, including Latin America and Asia-Pacific. In Asia-Pacific, the growth of the qPCR and dPCR instrumentation market is being led by the increased use of qPCR in blood donor testing & screening and diagnosis of infectious diseases and tropical diseases such as malaria.
Increasing geriatric population and the resulting incidents of chronic medical conditions such as cancer, coupled with broader application of PCR to study mutations and gene anomalies related to these diseases, are driving the adoption of qPCR and dPCR instrumentation in the Asia-Pacific region. Additionally, the falling cost of nucleic acid detection, quantification, and amplification techniques will also encourage the adoption of qPCR and dPCR instrumentation in research and diagnosis, particularly in the region’s developing, resource poor countries. PCR solution suppliers in Asia-Pacific have been increasingly focusing on establishing or expanding their production and sales network in the region. In recent years, various vendors have shifted their manufacturing units to the region in order to enjoy cost benefits and access the domestic markets, which in turn, is increasing awareness about the technology in the region, thereby contributing to its market growth.
Related Links:
Global Industry Analysts Inc.
Latest Industry News
- AMP Releases Best Practice Recommendations to Guide Clinical Laboratories Offering HRD Testing
- Illumina Acquires SomaLogic to Accelerate Proteomics Business
- Qiagen and Gencurix Partner on Development of QIAcuity Digital PCR IVD Assay
- QIAGEN and Incyte Enter into Precision Medicine Collaboration
- bioMérieux Acquires Day Zero Diagnostics Solutions and Technologies
- Aston University and BG Research Partner to Commercialize Groundbreaking Medical Diagnostic
- Fujirebio Collaborates with Stanford Medicine to Advance Infectious Disease Research
- QuidelOrtho to Acquire MDx Company LEX Diagnostics
- QIAGEN Enters into New Strategic Partnerships for Expanding MRD Testing Portfolio in Oncology
- Danaher and AstraZeneca Partner on Next Generation AI-Powered Diagnostics
- EuroMedLab 2025 Showcases Latest Technologies and Innovations in Laboratory Medicine
- Qiagen Acquires NGS Analysis Software Company Genoox
- Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
- Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
- New Collaboration to Advance Microbial Identification for Infectious Disease Diagnostics
- Tecan Acquires ELISA Immunoassay Assets from Revvity's Cisbio Bioassays
Channels
Clinical Chemistry
view channel
New Reference Measurement Procedure Standardizes Nucleic Acid Amplification Test Results
Nucleic acid amplification tests (NAATs) play a key role in diagnosing a wide range of infectious diseases. These tests are generally known for their high sensitivity and specificity, and they can be developed... Read more
Pen-Like Tool Quickly and Non-Invasively Detects Opioids from Skin
Opioid drugs such as fentanyl, morphine, and oxycodone are the primary substances associated with overdose cases in the United States. Standard drug screening procedures typically involve collecting blood,... Read moreMolecular Diagnostics
view channel
New Blood Test for Leukemia Risk Detection Could Replace Bone Marrow Sampling
Myelodysplastic syndrome (MDS) is a condition typically associated with aging, where blood stem cells fail to develop into fully functional blood cells. Early and accurate diagnosis is vital, as MDS can... Read more
Blood Test Detects Preeclampsia Risk Months Before Symptoms Appear
Preeclampsia, a pregnancy-related complication characterized by elevated blood pressure and organ dysfunction, remains a major contributor to maternal and infant health issues globally. Existing screening... Read moreHematology
view channel
Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results
Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more
First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes
Heparin dosing requires careful management to avoid both bleeding and clotting complications. In high-risk situations like extracorporeal membrane oxygenation (ECMO), mortality rates can reach about 50%,... Read moreImmunology
view channel
Blood Test Detects Organ Rejection in Heart Transplant Patients
Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Liquid Biopsy Approach to Transform Diagnosis, Monitoring and Treatment of Lung Cancer
Lung cancer continues to be a major contributor to cancer-related deaths globally, with its biological complexity and diverse regulatory processes making diagnosis and treatment particularly difficult.... Read more
Computational Tool Exposes Hidden Cancer DNA Changes Influencing Treatment Resistance
Structural changes in tumor DNA are among the most damaging genetic alterations in cancer, yet they often go undetected, particularly when tissue samples are degraded or of low quality. These hidden genomic... Read moreMicrobiology
view channel
Credit Card-Sized Test Boosts TB Detection in HIV Hotspots
Current tuberculosis (TB) tests face major limitations when it comes to accurately diagnosing the infection in individuals living with HIV. HIV, a frequent co-infection with TB, complicates detection by... Read more
Fecal Metabolite Profiling Predicts Mortality in Critically Ill Patients
Critically ill patients in medical intensive care units (MICUs) often suffer from conditions such as acute respiratory distress syndrome (ARDS) or sepsis, which are linked to reduced diversity of gut microbiota... Read more
Portable Molecular POC System Rules Out UTIs in Just 35 Minutes
Urinary tract infections (UTIs) represent a massive burden on patients and healthcare systems. There are over 400 million UTI cases globally each year, of which around 90% are in women. Fast and accurate... Read more
POC Lateral Flow Test Detects Deadly Fungal Infection Faster Than Existing Techniques
Diagnosing mucormycosis—an aggressive and often deadly fungal infection—remains a major challenge due to the disease’s rapid progression and the lack of fast, accurate diagnostic tools. The problem became... Read morePathology
view channel
Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response
Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Clinical AI Solution for Automatic Breast Cancer Grading Improves Diagnostic Accuracy
Labs that use traditional image analysis methods often suffer from bottlenecks and delays. By digitizing their pathology practices, labs can streamline their work, allowing them to take on larger caseloads... Read more
Saliva-Based Testing to Enable Early Detection of Cancer, Heart Disease or Parkinson’s
Saliva is one of the most accessible biological fluids, yet it remains underutilized in clinical practice. While saliva samples are used to perform genetic tests to determine, for example, paternity, the... Read moreTechnology
view channel
New POC Biosensing Technology Improves Detection of Molecular Biomarkers
Traditional diagnostic procedures in medicine typically involve sending a patient’s blood or tissue samples to clinical laboratories, where trained scientists perform testing and data interpretation.... Read more
Enhanced Lab Data Management and AI Critical to Labs of the Future, Finds Survey
Data plays a key role in the transformation of today’s digital laboratories, acting both as a key challenge and a catalyst for innovation, as revealed by a survey of over 150 scientists.... Read moreIndustry
view channel
AMP Releases Best Practice Recommendations to Guide Clinical Laboratories Offering HRD Testing
Homologous recombination deficiency (HRD) testing identifies tumors that are unable to effectively repair DNA damage through the homologous recombination repair pathway. This deficiency is often linked... Read more